Lilly Oncology Medical
@LillyOncMed
Dedicated to communicating the latest science & disease state education from Lilly Oncology. Intended for U.S. HCPs. Community Guidelines:
参加 March 2022
599 フォロー中 6.5K ファン
🩺SUNRAY 01 Part A | KRAS NSCLC Phase 3 Trial | Now Enrolling
A phase 3 trial evaluating a targeted, PD 1 inhibitor–based approach in treatment naïve KRAS G12C mutant NSCLC.
Click below for trial details & enrollment info
もっと見る
